The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice

Objective: to evaluate the clinical efficacy and safety of the targeted synthetic disease-modifying antirheumatic drug (DMARD) apremilast (AP; Otesla®) in patients with active psoriatic arthritis (PsA) at 14 and 26 weeks after starting the treatment and to identify the place of AP in the combination...

ver descrição completa

Detalhes bibliográficos

Principais autores:	E. Yu. Loginova, Yu. L. Korsakova, A. D. Koltakova, E. E. Gubar, P. L. Karpova, S. I. Glukhova, T. V. Korotaeva
Formato:	Artigo
Idioma:	Russo
Publicado em:	IMA PRESS LLC 2019-07-01
coleção:	Научно-практическая ревматология
Assuntos:	psoriatic arthritis comorbidity apremilast phosphodiesterase 4 inhibitor remission minimal disease activity
Acesso em linha:	https://rsp.mediar-press.net/rsp/article/view/2730
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!